At the ASCO-SITC Clinical Immuno-Oncology Symposium in San Francisco
Glenmark Pharmaceuticals has announced a presentation of preliminary biomarker findings from a Phase 1 study of GBR 1302 (NCT02829372), an investigational bispecific antibody, at the ASCO-SITC Clinical Immuno-Oncology Symposium in San Francisco. GBR 1302 is based on Glenmark's proprietary BEAT platform and simultaneously targets HER2 and the CD3 T cell co-receptor. HER2 is overexpressed in a variety of solid tumors and is a validated therapeutic target. This first-in-human study is ongoing and enrolling adults with progressive HER2-positive solid tumors who have not responded to available treatment options. The study is evaluating the safety and tolerability of GBR 1302, and exploring its anti-tumor activity.The discovery of agents targeting HER2 has greatly improved the treatment of a variety of cancers where it is overexpressed, said Kurt Stoeckli, President and Chief Scientific Officer at Glenmark Pharmaceuticals. Investigational treatments like bispecific antibodies that target a broad spectrum of HER2 expression levels on a variety of tumor tissues while simultaneously engaging tumor-infiltrating T cells have the potential to advance the treatment of these tumors, and may fulfill a substantial unmet medical need.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
